PGT-M Explained: Single-Gene Testing Before Embryo Transfer

Key Takeaways

PGT-M combines IVF, blastocyst biopsy, and a lab assay built around a known single-gene (monogenic) familial variant. It lowers the chance of transferring an embryo affected by that condition. It does not guarantee pregnancy, live birth, or a “risk-free” baby.

Key evidence: ASRM committee opinion: indications and management of PGT-M (2023) · ESHRE good practice recommendations for monogenic PGT (2020) · ACOG committee opinion: preimplantation genetic testing (2020)

Contents

• What is PGT-M?
• Who is it used for?
• How does the PGT-M process work?
• Why does preparation take time?
• What PGT-M can and cannot do
• Why genetic counselling matters
• Practical planning for international patients
• Questions worth discussing before deciding
• Dr Aksoy’s clinical perspective
• FAQ
• Sources

When a family already knows which gene is at stake, the next question is rarely “Can we test everything?” It is closer to: can we lower the chance of transferring an embryo that carries this disease — without pretending IVF becomes risk-free?

PGT-M — preimplantation genetic testing for monogenic disorders — used to be called PGD. The lab looks for the familial mutation you already documented (or a validated linkage strategy), not for every disease in the genome. That focus is the point. It can sharpen embryo selection for one target condition. It does not replace counselling, prenatal care, or honest IVF expectations.

What is PGT-M?

Short answer: PGT-M is a targeted DNA test on a few cells from an embryo — usually at the blastocyst stage — built around a known familial single-gene variant, so the team can favour transferring embryos not affected by that condition.

In practice it sits on top of IVF: stimulation, fertilisation, culture, then a trophectoderm biopsy and a lab assay designed for your variant. The aim is narrower than many online summaries suggest. It lowers the chance of transferring an embryo affected by that inherited condition (PMID: 37162432). It does not scan every chromosome — that is PGT-A — and it does not guarantee pregnancy or live birth.

Who is it used for?

Short answer: Couples usually consider it when one or both partners carry a known pathogenic variant, the risk of transmitting a monogenic disease is real, the familial mutation is confirmed (or can be), and they are ready for IVF, biopsy, freezing, and possibly a delayed transfer.

You will hear it discussed in contexts such as cystic fibrosis, thalassemia, sickle cell disease, Huntington disease, and selected cancer-predisposition syndromes. The genetics report and the law of the treatment country still decide what is possible. Being a “carrier” on a screening panel is not enough on its own. The laboratory needs a precise molecular target before embryo analysis is trustworthy.

How does the PGT-M process work?

Short answer: Think of seven steps: counselling and assay design; stimulation and egg retrieval; fertilisation (often ICSI) and culture to blastocyst; trophectoderm biopsy; targeted testing; ranking unaffected embryos; then transfer — often frozen once results are back.

Step one is the quiet bottleneck. Without a validated test design, asking for “fast” PGT-M does not make the process safer. It usually makes it less reliable.

Why does preparation take time?

Short answer: Before the first biopsy, the team confirms the exact familial variant on official reports, designs probes or linkage markers when needed, sets up controls, and lines up the IVF calendar with the genetics lab.

That work is invisible to patients until something is missing. Then everything waits. Biopsy, genetics, and freezing are also often billed separately from a base IVF cycle — see how add-ons are itemised on the cost of IVF page.

What PGT-M can and cannot do

Short answer: It can reduce the chance of transferring an embryo affected by the targeted monogenic condition. It cannot guarantee implantation or live birth, replace a separate PGT-A plan, create embryos if none develop, or promise that an unaffected embryo will always be there.

Can: lower the chance of transferring an embryo affected by the targeted monogenic condition.

Cannot:

• guarantee implantation or live birth,
• screen every chromosomal problem unless PGT-A (or another test) is separately planned and clinically justified,
• create embryos if none develop adequately,
• promise that an unaffected embryo will always be available for transfer.

Some cycles end with no transferable unaffected embryo. That outcome is hard. It should be named before stimulation starts (PMID: 37162432).

Morphology grades such as 4AA or 4BB still describe appearance only. They do not replace a genetic result — see IVF embryo grading.

Why genetic counselling matters

Short answer: Good PGT-M care is less about a single “yes/no” and more about shared clarity: which disease is targeted, how results are labelled, whether carrier embryos are acceptable, whether confirmatory prenatal testing is still offered, what happens if no embryo is suitable, and what the law allows where you treat — including Turkey’s assisted-reproduction rules.

Those conversations are medical and practical. Sometimes they are ethical as well. Rushing past them usually creates harder decisions later, not easier ones.

Practical planning for international patients

Short answer: Assay design often needs 4–8 weeks after official genetics reports arrive. Many couples plan three touches: a short assessment visit, a return for stimulation and biopsy, then a brief FET visit once results are ready.

• Visit 1 (assessment): day 2–3 hormones and ultrasound; genetic counselling; review of familial-variant reports.
• Assay design: 4–8 weeks, often followed remotely.
• Visit 2 (IVF cycle + biopsy): roughly 10–12 days of stimulation, then retrieval and biopsy (about 14 days on site). Embryos are usually frozen while results arrive (often another 10–14 days).
• Visit 3 (FET): return for 3–5 days for lining preparation, thaw, and transfer.
• Bring all official genetics reports — sequencing, carrier reports, prior counselling letters. Missing paperwork is the most common delay.

Questions worth discussing before deciding

Short answer: Take these to your medical team as a checklist, not as a sales script.

• What is the exact familial variant, and do official reports confirm it for both parents when relevant?
• Is the lab using direct sequencing, PCR probes, or linkage markers — and how often are results inconclusive?
• Are carrier embryos acceptable for transfer in our inheritance pattern, and what is clinic policy?
• What if the cycle ends with no transferable unaffected embryo?
• After pregnancy, is confirmatory prenatal testing (CVS / amniocentesis) still recommended — and why?
• What legal limits apply where we treat (Turkey or elsewhere) for PGT-M, sex selection, and how many embryos may be transferred?

Dr Aksoy’s clinical perspective

«I explain first that PGT-M is highly accurate, but it does not drive the risk of diagnostic error to zero. The sentence I use with couples is: PGT-M greatly lowers the chance that the baby carries the targeted disease; because it is a test on a few trophectoderm cells that later contribute to the placenta, we still offer confirmatory prenatal diagnosis with CVS or amniocentesis. ACOG and ASRM recommend that confirmatory prenatal testing be offered in every pregnancy after PGT-M — that means offer and counsel, not force the procedure on every couple. After genetic counselling, the couple may accept or decline. One practical point: NIPT does not replace CVS or amniocentesis when the goal is to exclude the specific familial monogenic variant.

«I strengthen the recommendation toward “I would almost always advise you to do it” when the disease is severe, early-onset, or life-threatening; when continuation of the pregnancy might depend on the result; when the assay was built around a de novo variant or limited family samples; when the laboratory reports reduced accuracy, technical limits, or an earlier inconclusive result followed by re-biopsy; or in selected X-linked situations where a carrier may develop symptoms. In a standard, well-validated familial assay with an unaffected result and no technical caveat, I still offer prenatal confirmation — but we weigh the small residual testing risk against the small procedural risk and against what the couple would do with the information: medical confirmation gives the highest confidence; how you balance the rest is a personal decision.

«On “carrier” embryos: the word does not mean the same thing in every inheritance pattern. In classic autosomal recessive disease, an embryo with one mutation is usually not affected; in X-linked, dominant, or manifesting-carrier conditions, I do not speak with the same reassurance. If an unaffected non-carrier embryo is available, I usually prefer transferring that first. If only unaffected carrier embryos remain in a classic recessive disease that does not clinically affect carriers, transfer can be reasonable — with the clear message that the child may pass the gene on and should seek genetic counselling before planning a family later. Ideally we settle these points in consent before results: are carriers transferable? Do non-carriers come first? What if only carriers remain? What about inconclusive results? But not every decision must be locked irreversibly before results. Unexpected or nuanced reports can be re-reviewed with clinical genetics without destroying any embryo. My line: we discuss preferences before results; after results we keep the right to re-read the genetic meaning — and we do not rush an irreversible choice.

«Finally, on “fast PGT-M” before assay design is finished: PGT-A looks at chromosomes in a general way; PGT-M builds a family-specific genetic fingerprint around your mutation. If biopsy is taken before that plan is ready, how the sample should be read may not yet be fixed. Linkage markers and haplotypes exist largely to reduce the risk that the mutant allele fails to amplify and an affected embryo looks unaffected (allele dropout). Skipping preparation can mean a false-negative direction, misclassification, an inconclusive result, a second biopsy after thaw and re-freeze, or even failure to build a trustworthy test despite embryos already existing — plus delay and extra cost. Egg retrieval does not always have to wait until assay design is complete: in older patients or low reserve, embryos can be created and frozen. Some laboratories accept blastocyst biopsy before full development if written coordination is already in place — but that acceptance must be written before biopsy, and tubing/amplification must match the planned PGT-M method. My sentence: we may not delay egg retrieval; we do not take a blind biopsy without laboratory agreement and a test plan. The right speed in PGT-M is not skipping preparation — it is coordinating the genetics lab, the IVF team, and family samples so embryo creation and assay development can run safely in parallel.»

Related reading in English:

• Can PGT be used for sex selection?
• IVF embryo grading explained
• IVF risks and practical considerations

FAQ

Is PGT-M the same as standard IVF?

Short answer: No. IVF is the platform. PGT-M adds biopsy and a targeted test for a known inherited condition.

Does PGT-M guarantee a healthy baby?

Short answer: No. It lowers the chance of transferring an embryo affected by the targeted disorder. Pregnancy and every other medical risk still need their own conversation.

Can PGT-M be done without knowing the exact mutation?

Short answer: Usually no. The laboratory needs a clearly identified familial variant — or another validated strategy — first.

Can a cycle end with no transferable embryo?

Short answer: Yes. Embryos may not develop, all may be affected, or no unaffected embryo may be available.

Is prenatal testing still needed after PGT-M?

Short answer: Often yes. Many programmes still offer confirmatory prenatal testing because embryo testing, while highly useful, is not treated as infallible.

Is PGT-M the same as PGT-A?

Short answer: No. PGT-M asks about one monogenic disease. PGT-A asks about chromosome copy number. They answer different questions and are combined only when clinically justified.

Sources

• Practice Committee of the American Society for Reproductive Medicine (ASRM). “Indications and management of preimplantation genetic testing for monogenic conditions: a committee opinion.” Fertil Steril. 2023; 119(5): 779-792. PMID: 37162432
• ESHRE PGT Consortium. “ESHRE PGT Consortium good practice recommendations for the detection of monogenic disorders.” Hum Reprod Open. 2020; 2020(3): hoaa025. PMID: 32500103
• American College of Obstetricians and Gynecologists (ACOG). “Preimplantation Genetic Testing: ACOG Committee Opinion, Number 799.” Obstet Gynecol. 2020; 135(3): e66-e77. PMID: 32080053
• Gutiérrez-Mateo C et al. “Preimplantation genetic diagnosis of single-gene disorders: experience with more than 200 cycles conducted by a reference laboratory in the United States.” Fertil Steril. 2009; 92(5): 1544-1556. PMID: 18937943
• De Rycke M et al. “ESHRE PGD Consortium data collection XIV-XV: cycles from January 2011 to December 2012 with pregnancy follow-up to October 2013.” Hum Reprod. 2017; 32(10): 1974-1994. PMID: 29117384

Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a founding member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed · ORCID · LinkedIn

Read full profile → Instagram YouTube

The content has been created by Dr. Senai Aksoy and medically approved.